To explore the value of BMI1High;CHD7Low molecular signature as a potential predictive marker of response in future clinical trials, we analyzed a cohort of MB patients where proteogenomic analysis had been performed on surgically resected tumor samples.35 Analysis of ERK1 and ERK2 kinase activity scores obtained from phospho-proteomic data showed a positive and negative correlation with BMI1 and CHD7 expression level respectively, suggesting a role for the CHD7-BMI1-MAPK regulatory axis in patients’ tumor samples as well (Figure 6A,B). This evidence concerns the gene MAPK3 and neoplasm.